Abrogation of Postprandial Triglyceridemia with Dual PPAR α/γ Agonist in Type 2 Diabetes Mellitus: a Randomized, Placebo-controlled Study

Overview

Journal Acta Diabetol

Specialty Endocrinology

Date 2020 Feb 8

PMID 32030508

Citations 8

Authors

Ashu Rastogi

Richard L Dunbar

Hemant P Thacker

Jayesh Bhatt

Krupi Parmar

Deven V Parmar

Affiliations

Soon will be listed here.

Abstract

Aims: Lowering postprandial lipemia may mitigate cardiovascular risk in patients with diabetic dyslipidemia. This study was aimed to investigate whether saroglitazar suppresses postprandial lipemia in patients with diabetes and dyslipidemia.

Methods: This was a 12-week, prospective, multicenter, randomized, double-blinded, placebo-controlled study of saroglitazar in patients with diabetes and dyslipidemia. Thirty patients were randomized (1:1) to receive saroglitazar 4 mg or placebo orally once daily with metformin for 12 weeks. The primary endpoint was change in plasma triglyceride (TG) area under the curve (AUC) on a standardized 8-h fat tolerance test.

Results: Thirty participants were randomized for interventions and eventually data of 19 participants qualified for per protocol analyses. Mean (SD) age in saroglitazar was 53.1 (8.8) years and 54.9 (7.7) years in placebo group. After 12 weeks, saroglitazar significantly lowered postprandial TG-AUC by - 458.3 (144.0) (- 25.7%, 95% CI - 765.1 to - 151.4) versus an increase of + 10.9 (157.9) (+ 0.5%, 95% CI - 325.6 to 347.3) mg/dL h in placebo group (P < 0.05). Saroglitazar lowered postprandial TG incremental AUC versus placebo: - 329.4 (89.9) (- 59%) versus + 80.4 (99.4) (+ 10%) mg/dL h (P < 0.05). HbA1c (%) decreased by - 0.36 (0.42) in the saroglitazar group as compared to an increase of + 1.26 (0.46) (P < 0.05) with placebo.

Conclusions: The saroglitazar treatment significantly improved postprandial TGs in people with diabetic dyslipidemia.

Trial Registration: Clinical Trial Registry of India; trial Registration No.: CTRI/2015/06/005845 and Date of registration: June 02, 2015.

Citing Articles

Hypoglycemic Effects and Quality Marker Screening of Lindl. at Different Growth Years.

Luo Y, Yang D, Xu Y, Wu D, Tan D, Qin L Molecules. 2024; 29(3).

PMID: 38338442 PMC: 10856227. DOI: 10.3390/molecules29030699.

Dual PPRαϒ Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Junior A, Oliveira V, Oliveira I, de Sousa A, Santana A, Carvalho D J Clin Med. 2023; 12(17).

PMID: 37685742 PMC: 10488550. DOI: 10.3390/jcm12175674.

Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Durga D, Mounika N, Mudimala P, Adela R Clin Drug Investig. 2022; 42(12):1049-1064.

PMID: 36329293 DOI: 10.1007/s40261-022-01219-6.

Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis.

Liang T, Xie X, Wu L, Li L, Yang L, Gao H Front Nutr. 2022; 9:825897.

PMID: 35923194 PMC: 9339904. DOI: 10.3389/fnut.2022.825897.

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.

Chhabra M, Vidyasagar K, Gudi S, Sharma J, Sharma R, Rashid M PLoS One. 2022; 17(7):e0269531.

PMID: 35776741 PMC: 9249226. DOI: 10.1371/journal.pone.0269531.

References

Bornfeldt K, Tabas I . Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011; 14(5):575-85. PMC: 3217209. DOI: 10.1016/j.cmet.2011.07.015. View

Ginsberg H . Insulin resistance and cardiovascular disease. J Clin Invest. 2000; 106(4):453-8. PMC: 380256. DOI: 10.1172/JCI10762. View

deGoma E, Davis M, Dunbar R, Mohler 3rd E, Greenland P, French B . Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013; 229(2):517-23. PMC: 4066302. DOI: 10.1016/j.atherosclerosis.2013.03.012. View

Bansal S, Buring J, Rifai N, Mora S, Sacks F, Ridker P . Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007; 298(3):309-16. DOI: 10.1001/jama.298.3.309. View

Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A . Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994; 106(1):83-97. DOI: 10.1016/0021-9150(94)90085-x. View

Riccardi G, Rivellese A . Dietary treatment of the metabolic syndrome--the optimal diet. Br J Nutr. 2000; 83 Suppl 1:S143-8. DOI: 10.1017/s0007114500001082. View

Karpe F . Postprandial lipemia--effect of lipid-lowering drugs. Atheroscler Suppl. 2002; 3(1):41-6. DOI: 10.1016/s1567-5688(01)00004-6. View

Bae J, Bassenge E, Lee H, Park K, Park C, Park K . Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. Atherosclerosis. 2001; 158(1):165-71. DOI: 10.1016/s0021-9150(01)00408-7. View

van Wijk J, de Koning E, Cabezas M, Rabelink T . Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care. 2005; 28(4):844-9. DOI: 10.2337/diacare.28.4.844. View

10.

Chappuis B, Braun M, Stettler C, Allemann S, Diem P, Lumb P . Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev. 2007; 23(5):392-9. DOI: 10.1002/dmrr.715. View

11.

Roche H, Gibney M . Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. Am J Clin Nutr. 2000; 71(1 Suppl):232S-7S. DOI: 10.1093/ajcn/71.1.232s. View

12.

Usman M, Qamar A, Gadi R, Lilly S, Goel H, Hampson J . Extended-release niacin acutely suppresses postprandial triglyceridemia. Am J Med. 2012; 125(10):1026-35. PMC: 4170918. DOI: 10.1016/j.amjmed.2012.03.017. View

13.

King J, Crouse J, Terry J, Morgan T, Spray B, MILLER N . Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med. 1994; 97(4):323-31. DOI: 10.1016/0002-9343(94)90298-4. View

14.

Kumar V, Madhu S, Singh G, Gambhir J . Post-prandial hypertriglyceridemia in patients with type 2 diabetes mellitus with and without macrovascular disease. J Assoc Physicians India. 2011; 58:603-7. View

15.

Westphal S, Wiens L, Guttler K, Dierkes J, Luley C . Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia. Atherosclerosis. 2003; 171(2):369-77. DOI: 10.1016/j.atherosclerosis.2003.08.030. View

16.

Freiberg J, Tybjaerg-Hansen A, Skov Jensen J, Nordestgaard B . Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008; 300(18):2142-52. DOI: 10.1001/jama.2008.621. View

17.

Bhatt D, Steg P, Miller M, Brinton E, Jacobson T, Ketchum S . Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2018; 380(1):11-22. DOI: 10.1056/NEJMoa1812792. View

18.

Jani R, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A . A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy.... Diabetes Technol Ther. 2013; 16(2):63-71. PMC: 3894674. DOI: 10.1089/dia.2013.0253. View

19.

Kolovou G, Mikhailidis D, Kovar J, Lairon D, Nordestgaard B, Ooi T . Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011; 9(3):258-70. DOI: 10.2174/157016111795495549. View

20.

Jeppesen J, Zhou M, Chen Y, Reaven G . Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM. Diabetologia. 1994; 37(8):781-7. DOI: 10.1007/BF00404335. View